Cancer Therapy with Co-delivery of Camptothecin
Abstract
This essay has discussed various ways by which two or more than two drugs have been combined with Camptothecin through nanoparticles in order to yield anti-cancer therapy effectiveness. A systematic and comprehensive literature review has been prepared to show such combinations demonstrated high anticancer efficacy.
Keywords:
Combination drug therapy, Camptothecin, pharmaceutics
Downloads
Download data is not yet available.
References
1. Hsiang Y-H, Hertzberg R, Hecht S, and Liu L. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. Journal of Biological Chemistry. 1985, 260: 14873-14878
2. Cheng X. DEVELOPING ORGANIC AND INORGANIC NANOMEDICINE FOR CANCER THERAPY. Journal of Drug Delivery and Therapeutics. 2017, 7: 1-4
3. Cheng X, and Lee R J. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev. 2016, 99: 129-137; doi: 10.1016/j.addr.2016.01.022.
4. Liu F, Sun Y, Kang C, and Zhu H. Pegylated Drug Delivery Systems: From Design to Biomedical Applications. Nano LIFE. 2016, 6: 1642002
5. Cheng X, Liu Q, Li H, Kang C, Liu Y, Guo T, et al. Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer. Pharm Res. 2017, 34: 310-320; doi: 10.1007/s11095-016-2063-5.
6. Li Q-Y, Zu Y-G, Shi R-Z, and Yao L-P. Review camptothecin: current perspectives. Current medicinal chemistry. 2006, 13: 2021-2039
7. Sriram D, Yogeeswari P, Thirumurugan R, and Ratan Bal T. Camptothecin and its analogues: a review on their chemotherapeutic potential. Natural product research. 2005, 19: 393-412
8. Li H, Cheng X, Liu Y, Lee Y B, Kim D J, Ahn C-h, et al. Folate receptor-targeted lipid coated albumin nanoparticles (F-LCAN) for therapeutic delivery of RX-0201 (Archexin®), an antisense oligonucleotide against Akt-1. 2016,
9. Li H, Quan J, Zhang M, Yung B C, Cheng X, Liu Y, et al. Lipid-Albumin Nanoparticles (LAN) for Therapeutic Delivery of Antisense Oligonucleotide against HIF-1alpha. Mol Pharm. 2016, 13: 2555-2562; doi: 10.1021/acs.molpharmaceut.6b00363.
10. Kang C, Sun Y, Wang M, and Cheng X. Nanosized camptothecin conjugates for single and combined drug delivery. European Journal of BioMedical Research. 2016, 2: 8-14
11. Kang C, Sun Y, Zhu J, Li W, Zhang A, Kuang T, et al. Delivery of Nanoparticles for Treatment of Brain Tumor. Current Drug Metabolism. 2016, 17: 745-754
12. Sun Y, Kang C, Liu F, and Song L. Delivery of Antipsychotics with Nanoparticles. Drug Development Research. 2016, 77: 393-399
13. Sun Y, Kang C, Zhang A, Liu F, Hu J, Zhong X, et al. Co-delivery of dual-drugs with nanoparticle to overcome multidrug resistance. European Journal of BioMedical Research. 2016, 2: 12-18
14. Duan Y, Pei K, Cai H, Tu S, Cheng X, Zhang Z, et al. Strategy of integrated evaluation on treatment of traditional Chinese medicine as ‘interaction of system to system’and establishment of novel fuzzy target contribution recognition with herb-pairs, a case study on Astragali Radix-Fructus Corni. Molecular and Cellular Endocrinology. 2016, 434: 219-237
15. Duan Y, Pei K, Cai H, Tu S, Zhang Z, Cheng X, et al. Bioactivity evaluation-based ultra high-performance liquid chromatography coupled with electrospray ionization tandem quadrupole-time-of-flight mass spectrometry and novel distinction of multi-subchemome compatibility recognition strategy with Astragali Radix-Fructus Corni herb-pair as a case study. Journal of pharmaceutical and biomedical analysis. 2016, 129: 514-534
16. Tai W, Mo R, Lu Y, Jiang T, and Gu Z. Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugs. Biomaterials. 2014, 35: 7194-7203; doi: 10.1016/j.biomaterials.2014.05.004.
17. Chen Y, Bian Y, Sun Y, Kang C, Yu S, Fu T, et al. Identification of 4-aminoquinoline core for the design of new cholinesterase inhibitors. PeerJ. 2016, 4: e2140
18. Han R, Sun Y, Kang C, Sun H, and Wei W. Amphiphilic dendritic nanomicelle-mediated co-delivery of 5-fluorouracil and doxorubicin for enhanced therapeutic efficacy. Journal of Drug Targeting. 2017, 25: 140-148
19. Sun Y, Kang C, Yao Z, Liu F, and Zhou Y. Peptide-Based Ligand for Active Delivery of Liposomal Doxorubicin. Nano LIFE. 2016, 6: 1642004
20. Kang C, Qin J, Osei W, and Hu K. Regulation of protein kinase C-epsilon and its age-dependence. Biochemical and Biophysical Research Communications. 2017, 482: 1201-1206
21. Zhang W, Zhou X, Liu T, Ma D, and Xue W. Supramolecular hydrogels co-loaded with camptothecin and doxorubicin for sustainedly synergistic tumor therapy. Journal of Materials Chemistry B. 2015, 3: 2127-2136
22. Qiao H, Fang D, Chen J, Sun Y, Kang C, Di L, et al. Orally delivered polycurcumin responsive to bacterial reduction for targeted therapy of inflammatory bowel disease. Drug Delivery. 2017, 24: 233-242
23. Sun Y, and Kang C. Self-Assembly of Peptides into Hydrogel. Journal of Organic & Inorganic Chemistry. 2016,
24. Song L, Kang C, Sun Y, Huang W, Liu W, and Qian Z. Crocetin Inhibits Lipopolysaccharide-Induced Inflammatory Response in Human Umbilical Vein Endothelial Cells. Cellular Physiology and Biochemistry. 2016, 40: 443-452
25. Waller A P, George M, Kalyanasundaram A, Kang C, Periasamy M, Hu K, et al. GLUT12 functions as a basal and insulin-independent glucose transporter in the heart. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2013, 1832: 121-127
26. Xiao B, Si X, Han M K, Viennois E, Zhang M, and Merlin D. Co-delivery of camptothecin and curcumin by cationic polymeric nanoparticles for synergistic colon cancer combination chemotherapy. Journal of Materials Chemistry B. 2015, 3: 7724-7733
27. XU S-h, Chen K, CHEN M-l, ZHOU P-p, HE G-w, CUI Y-j, et al. Dynamic expression of AQP4 in early stageof ischemia/reperfusion rats and cerebral edema. Chinese Pharmacological Bulletin. 2016: 1433-1441
28. Zhang Y, Xiao C, Li M, Chen J, Ding J, He C, et al. Coâ€delivery of 10â€Hydroxycamptothecin with Doxorubicin Conjugated Prodrugs for Enhanced Anticancer Efficacy. Macromolecular bioscience. 2013, 13: 584-594
29. Xue X, Zhao N-Y, Yu H-T, Sun Y, Kang C, Huang Q-B, et al. Discovery of novel inhibitors disrupting HIF-1α/von Hippel–Lindau interaction through shape-based screening and cascade docking. PeerJ. 2016, 4: e2757
30. Yang Z, Xie J, Zhu J, Kang C, Chiang C, Wang X, et al. Functional exosome-mimic for delivery of siRNA to cancer: in vitro and in vivo evaluation. Journal of Controlled Release. 2016, 243: 160-171
31. Yao Z, Sun Y, and Kang C. Structure and Self-Assembly of Multicolored Naphthalene Diimides Semiconductor. Nano LIFE. 2016, 6: 1642007
32. Liao L, Liu J, Dreaden E C, Morton S W, Shopsowitz K E, Hammond P T, et al. A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. Journal of the American Chemical Society. 2014, 136: 5896
33. Zhong X, Sun Y, Kang C, and Wan G. The theory of dielectrophoresis and its applications on medical and materials research. European Journal of BioMedical Research. 2017, 2: 7-11
2. Cheng X. DEVELOPING ORGANIC AND INORGANIC NANOMEDICINE FOR CANCER THERAPY. Journal of Drug Delivery and Therapeutics. 2017, 7: 1-4
3. Cheng X, and Lee R J. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev. 2016, 99: 129-137; doi: 10.1016/j.addr.2016.01.022.
4. Liu F, Sun Y, Kang C, and Zhu H. Pegylated Drug Delivery Systems: From Design to Biomedical Applications. Nano LIFE. 2016, 6: 1642002
5. Cheng X, Liu Q, Li H, Kang C, Liu Y, Guo T, et al. Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer. Pharm Res. 2017, 34: 310-320; doi: 10.1007/s11095-016-2063-5.
6. Li Q-Y, Zu Y-G, Shi R-Z, and Yao L-P. Review camptothecin: current perspectives. Current medicinal chemistry. 2006, 13: 2021-2039
7. Sriram D, Yogeeswari P, Thirumurugan R, and Ratan Bal T. Camptothecin and its analogues: a review on their chemotherapeutic potential. Natural product research. 2005, 19: 393-412
8. Li H, Cheng X, Liu Y, Lee Y B, Kim D J, Ahn C-h, et al. Folate receptor-targeted lipid coated albumin nanoparticles (F-LCAN) for therapeutic delivery of RX-0201 (Archexin®), an antisense oligonucleotide against Akt-1. 2016,
9. Li H, Quan J, Zhang M, Yung B C, Cheng X, Liu Y, et al. Lipid-Albumin Nanoparticles (LAN) for Therapeutic Delivery of Antisense Oligonucleotide against HIF-1alpha. Mol Pharm. 2016, 13: 2555-2562; doi: 10.1021/acs.molpharmaceut.6b00363.
10. Kang C, Sun Y, Wang M, and Cheng X. Nanosized camptothecin conjugates for single and combined drug delivery. European Journal of BioMedical Research. 2016, 2: 8-14
11. Kang C, Sun Y, Zhu J, Li W, Zhang A, Kuang T, et al. Delivery of Nanoparticles for Treatment of Brain Tumor. Current Drug Metabolism. 2016, 17: 745-754
12. Sun Y, Kang C, Liu F, and Song L. Delivery of Antipsychotics with Nanoparticles. Drug Development Research. 2016, 77: 393-399
13. Sun Y, Kang C, Zhang A, Liu F, Hu J, Zhong X, et al. Co-delivery of dual-drugs with nanoparticle to overcome multidrug resistance. European Journal of BioMedical Research. 2016, 2: 12-18
14. Duan Y, Pei K, Cai H, Tu S, Cheng X, Zhang Z, et al. Strategy of integrated evaluation on treatment of traditional Chinese medicine as ‘interaction of system to system’and establishment of novel fuzzy target contribution recognition with herb-pairs, a case study on Astragali Radix-Fructus Corni. Molecular and Cellular Endocrinology. 2016, 434: 219-237
15. Duan Y, Pei K, Cai H, Tu S, Zhang Z, Cheng X, et al. Bioactivity evaluation-based ultra high-performance liquid chromatography coupled with electrospray ionization tandem quadrupole-time-of-flight mass spectrometry and novel distinction of multi-subchemome compatibility recognition strategy with Astragali Radix-Fructus Corni herb-pair as a case study. Journal of pharmaceutical and biomedical analysis. 2016, 129: 514-534
16. Tai W, Mo R, Lu Y, Jiang T, and Gu Z. Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugs. Biomaterials. 2014, 35: 7194-7203; doi: 10.1016/j.biomaterials.2014.05.004.
17. Chen Y, Bian Y, Sun Y, Kang C, Yu S, Fu T, et al. Identification of 4-aminoquinoline core for the design of new cholinesterase inhibitors. PeerJ. 2016, 4: e2140
18. Han R, Sun Y, Kang C, Sun H, and Wei W. Amphiphilic dendritic nanomicelle-mediated co-delivery of 5-fluorouracil and doxorubicin for enhanced therapeutic efficacy. Journal of Drug Targeting. 2017, 25: 140-148
19. Sun Y, Kang C, Yao Z, Liu F, and Zhou Y. Peptide-Based Ligand for Active Delivery of Liposomal Doxorubicin. Nano LIFE. 2016, 6: 1642004
20. Kang C, Qin J, Osei W, and Hu K. Regulation of protein kinase C-epsilon and its age-dependence. Biochemical and Biophysical Research Communications. 2017, 482: 1201-1206
21. Zhang W, Zhou X, Liu T, Ma D, and Xue W. Supramolecular hydrogels co-loaded with camptothecin and doxorubicin for sustainedly synergistic tumor therapy. Journal of Materials Chemistry B. 2015, 3: 2127-2136
22. Qiao H, Fang D, Chen J, Sun Y, Kang C, Di L, et al. Orally delivered polycurcumin responsive to bacterial reduction for targeted therapy of inflammatory bowel disease. Drug Delivery. 2017, 24: 233-242
23. Sun Y, and Kang C. Self-Assembly of Peptides into Hydrogel. Journal of Organic & Inorganic Chemistry. 2016,
24. Song L, Kang C, Sun Y, Huang W, Liu W, and Qian Z. Crocetin Inhibits Lipopolysaccharide-Induced Inflammatory Response in Human Umbilical Vein Endothelial Cells. Cellular Physiology and Biochemistry. 2016, 40: 443-452
25. Waller A P, George M, Kalyanasundaram A, Kang C, Periasamy M, Hu K, et al. GLUT12 functions as a basal and insulin-independent glucose transporter in the heart. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2013, 1832: 121-127
26. Xiao B, Si X, Han M K, Viennois E, Zhang M, and Merlin D. Co-delivery of camptothecin and curcumin by cationic polymeric nanoparticles for synergistic colon cancer combination chemotherapy. Journal of Materials Chemistry B. 2015, 3: 7724-7733
27. XU S-h, Chen K, CHEN M-l, ZHOU P-p, HE G-w, CUI Y-j, et al. Dynamic expression of AQP4 in early stageof ischemia/reperfusion rats and cerebral edema. Chinese Pharmacological Bulletin. 2016: 1433-1441
28. Zhang Y, Xiao C, Li M, Chen J, Ding J, He C, et al. Coâ€delivery of 10â€Hydroxycamptothecin with Doxorubicin Conjugated Prodrugs for Enhanced Anticancer Efficacy. Macromolecular bioscience. 2013, 13: 584-594
29. Xue X, Zhao N-Y, Yu H-T, Sun Y, Kang C, Huang Q-B, et al. Discovery of novel inhibitors disrupting HIF-1α/von Hippel–Lindau interaction through shape-based screening and cascade docking. PeerJ. 2016, 4: e2757
30. Yang Z, Xie J, Zhu J, Kang C, Chiang C, Wang X, et al. Functional exosome-mimic for delivery of siRNA to cancer: in vitro and in vivo evaluation. Journal of Controlled Release. 2016, 243: 160-171
31. Yao Z, Sun Y, and Kang C. Structure and Self-Assembly of Multicolored Naphthalene Diimides Semiconductor. Nano LIFE. 2016, 6: 1642007
32. Liao L, Liu J, Dreaden E C, Morton S W, Shopsowitz K E, Hammond P T, et al. A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. Journal of the American Chemical Society. 2014, 136: 5896
33. Zhong X, Sun Y, Kang C, and Wan G. The theory of dielectrophoresis and its applications on medical and materials research. European Journal of BioMedical Research. 2017, 2: 7-11
Crossmark
Statistics
409 Views | 469 Downloads
How to Cite
1.
Zhang S. Cancer Therapy with Co-delivery of Camptothecin. JDDT [Internet]. 14May2017 [cited 18Apr.2024];7(3):76-9. Available from: https://www.jddtonline.info/index.php/jddt/article/view/1450
Section
Mini Review
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.